While Editas Medicine Inc has underperformed by -3.89%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EDIT rose by 94.49%, with highs and lows ranging from $4.12 to $0.91, whereas the simple moving average jumped by 31.01% in the last 200 days.
On April 28, 2025, H.C. Wainwright started tracking Editas Medicine Inc (NASDAQ: EDIT) recommending Buy. A report published by JP Morgan on December 16, 2024, Downgraded its rating to ‘Underweight’ for EDIT. Stifel December 13, 2024d the rating to Hold on December 13, 2024, and set its price target from $11 to $3. Chardan Capital Markets December 13, 2024d its ‘Buy’ rating to ‘Neutral’ for EDIT, as published in its report on December 13, 2024. Wells Fargo’s report from December 11, 2024 suggests a price prediction of $4 for EDIT shares, giving the stock a ‘Equal Weight’ rating. BofA Securities also rated the stock as ‘Underperform’.
Analysis of Editas Medicine Inc (EDIT)
Further, the quarter-over-quarter increase in sales is 597.47%, showing a positive trend in the upcoming months.
Editas Medicine Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -188.58% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.77, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and EDIT has an average volume of 2.47M. On a monthly basis, the volatility of the stock is set at 8.25%, whereas on a weekly basis, it is put at 5.86%, with a loss of -9.19% over the past seven days. Furthermore, long-term investors anticipate a median target price of $3.89, showing growth from the present price of $2.47, which can serve as yet another indication of whether EDIT is worth investing in or should be passed over.
How Do You Analyze Editas Medicine Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.90%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 47.45% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
